inclusion criteria: * clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition. * positive test for sars-cov-2 within ≤5 days (if \>1 test, the first positive is within ≤5 days). tests may include an institutional-based nucleic acid amplification test (naat), or any protocol-approved rapid test. * within ≤5 days from symptom onset, if symptomatic from current sars-cov-2 infection. * agrees to not participate in another clinical trial for the treatment or management of sars-cov-2 infection through day 7, or until hospitalized or significant disease progression if prior to day 7 (defined by ordinal category 4 or 5). * participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through day 28. ongoing immunosuppressive condition or immunosuppressive treatment, includes: 1. steroids equivalent to prednisone \> 10 mg/day for at least the last 28 days 2. rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy 3. antirejection medicine after solid organ or stem cell transplantation 4. cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months 5. primary or acquired severe b- or t-lymphocyte immune dysfunction 6. hiv infection 7. splenectomy or functional asplenia

inclusion criteria: * clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition. * positive test for sars-cov-2 within ≤5 days (if \>1 test, the first positive is within ≤5 days). tests may include an institutional-based nucleic acid amplification test (naat), or any protocol-approved rapid test. * within ≤5 days from symptom onset, if symptomatic from current sars-cov-2 infection. * agrees to not participate in another clinical trial for the treatment or management of sars-cov-2 infection through day 7, or until hospitalized or significant disease progression if prior to day 7 (defined by ordinal category 4 or 5). * participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through day 28. ongoing immunosuppressive condition or immunosuppressive treatment, includes: 1. steroids equivalent to prednisone \> 10 mg/day for at least the last 28 days 2. rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy 3. antirejection medicine after solid organ or stem cell transplantation 4. cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months 5. primary or acquired severe b- or t-lymphocyte immune dysfunction 6. hiv infection 7. splenectomy or functional asplenia

inclusion criteria: clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition. positive test for sars-cov-2 within ≤5 days (if >1 test, the first positive is within ≤5 days). tests may include an institutional-based nucleic acid amplification test (naat), or any protocol-approved rapid test. within ≤5 days from symptom onset, if symptomatic from current sars-cov-2 infection. agrees to not participate in another clinical trial for the treatment or management of sars-cov-2 infection through day 7, or until hospitalized or significant disease progression if prior to day 7 (defined by ordinal category 4 or 5). participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through day 28. ongoing immunosuppressive condition or immunosuppressive treatment, includes: steroids equivalent to prednisone > 10 mg/day for at least the last 28 days rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy antirejection medicine after solid organ or stem cell transplantation cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months primary or acquired severe b- or t-lymphocyte immune dysfunction hiv infection splenectomy or functional asplenia

inclusion criteria: clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition. positive test for sars-cov-2 within ≤5 days (if >1 test, the first positive is within ≤5 days). tests may include an institutional-based nucleic acid amplification test (naat), or any protocol-approved rapid test. within ≤5 days from symptom onset, if symptomatic from current sars-cov-2 infection. agrees to not participate in another clinical trial for the treatment or management of sars-cov-2 infection through day 7, or until hospitalized or significant disease progression if prior to day 7 (defined by ordinal category 4 or 5). participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through day 28. ongoing immunosuppressive condition or immunosuppressive treatment, includes: steroids equivalent to prednisone > 10 mg/day for at least the last 28 days rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy antirejection medicine after solid organ or stem cell transplantation cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months primary or acquired severe b- or t-lymphocyte immune dysfunction hiv infection splenectomy or functional asplenia

inclusion criteria: - clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition. - positive test for sars-cov-2 within ≤5 days (if >1 test, the first positive is within ≤5 days). tests may include an institutional-based nucleic acid amplification test (naat), or any protocol-approved rapid test. - within ≤5 days from symptom onset, if symptomatic from current sars-cov-2 infection. - agrees to not participate in another clinical trial for the treatment or management of sars-cov-2 infection through day 7, or until hospitalized or significant disease progression if prior to day 7 (defined by ordinal category 4 or 5). - participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through day 28. ongoing immunosuppressive condition or immunosuppressive treatment, includes: 1. steroids equivalent to prednisone > 10 mg/day for at least the last 28 days 2. rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy 3. antirejection medicine after solid organ or stem cell transplantation 4. cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months 5. primary or acquired severe b- or t-lymphocyte immune dysfunction 6. hiv infection 7. splenectomy or functional asplenia

inclusion criteria: - clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition. - positive test for sars-cov-2 within ≤5 days (if >1 test, the first positive is within ≤5 days). tests may include an institutional-based nucleic acid amplification test (naat), or any protocol-approved rapid test. - within ≤5 days from symptom onset, if symptomatic from current sars-cov-2 infection. - agrees to not participate in another clinical trial for the treatment or management of sars-cov-2 infection through day 7, or until hospitalized or significant disease progression if prior to day 7 (defined by ordinal category 4 or 5). - participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through day 28. ongoing immunosuppressive condition or immunosuppressive treatment, includes: 1. steroids equivalent to prednisone > 10 mg/day for at least the last 28 days 2. rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy 3. antirejection medicine after solid organ or stem cell transplantation 4. cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months 5. primary or acquired severe b- or t-lymphocyte immune dysfunction 6. hiv infection 7. splenectomy or functional asplenia